FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164914380> ?p ?o ?g. }

• W3164914380 endingPage "804" @default.
• W3164914380 startingPage "804" @default.
• W3164914380 abstract "Sustained-release (SR) formulations may appear advantageous in first-in-human (FIH) study of innovative medicines. The newly developed SR matrix tablets require prolonged maintenance of API concentration in plasma and should be reliably assessed for the risk of uncontrolled release of the drug. In the present study, we describe the development of a robust SR matrix tablet with a novel G-protein-coupled receptor 40 (GPR40) agonist for first-in-human studies and introduce a general workflow for the successful development of SR formulations for innovative APIs. The hydrophilic matrix tablets containing the labeled API dose of 5, 30, or 120 mg were evaluated with several methods: standard USP II dissolution, bio-predictive dissolution tests, and the texture and matrix formation analysis. The standard dissolution tests allowed preselection of the prototypes with the targeted dissolution rate, while the subsequent studies in physiologically relevant conditions revealed unwanted and potentially harmful effects, such as dose dumping under an increased mechanical agitation. The developed formulations were exceptionally robust toward the mechanical and physicochemical conditions of the bio-predictive tests and assured a comparable drug delivery rate regardless of the prandial state and dose labeled. In conclusion, the introduced development strategy, when implemented into the development cycle of SR formulations with innovative APIs, may allow not only to reduce the risk of formulation-related failure of phase I clinical trial but also effectively and timely provide safe and reliable medicines for patients in the trial and their further therapy." @default.
• W3164914380 created "2021-06-07" @default.
• W3164914380 creator A5001730543 @default.
• W3164914380 creator A5004710716 @default.
• W3164914380 creator A5029995906 @default.
• W3164914380 creator A5032197327 @default.
• W3164914380 creator A5032443332 @default.
• W3164914380 creator A5039148956 @default.
• W3164914380 creator A5056772996 @default.
• W3164914380 creator A5073051707 @default.
• W3164914380 creator A5074594600 @default.
• W3164914380 creator A5080949484 @default.
• W3164914380 creator A5081374452 @default.
• W3164914380 creator A5091335333 @default.
• W3164914380 date "2021-05-28" @default.
• W3164914380 modified "2023-10-13" @default.
• W3164914380 title "Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical Trial" @default.
• W3164914380 cites W1499768710 @default.
• W3164914380 cites W1603245870 @default.
• W3164914380 cites W1607423153 @default.
• W3164914380 cites W1813104943 @default.
• W3164914380 cites W1907439560 @default.
• W3164914380 cites W1969300284 @default.
• W3164914380 cites W1976383678 @default.
• W3164914380 cites W1979751349 @default.
• W3164914380 cites W1992852507 @default.
• W3164914380 cites W1993992613 @default.
• W3164914380 cites W1995051336 @default.
• W3164914380 cites W2003480886 @default.
• W3164914380 cites W2004623177 @default.
• W3164914380 cites W2009249933 @default.
• W3164914380 cites W2009394479 @default.
• W3164914380 cites W2015795623 @default.
• W3164914380 cites W2027498139 @default.
• W3164914380 cites W2027507514 @default.
• W3164914380 cites W2031104076 @default.
• W3164914380 cites W2033798101 @default.
• W3164914380 cites W2034613829 @default.
• W3164914380 cites W2040662537 @default.
• W3164914380 cites W2041179090 @default.
• W3164914380 cites W2071593616 @default.
• W3164914380 cites W2087496871 @default.
• W3164914380 cites W2088515694 @default.
• W3164914380 cites W2106730245 @default.
• W3164914380 cites W2116059552 @default.
• W3164914380 cites W2319334300 @default.
• W3164914380 cites W2328471569 @default.
• W3164914380 cites W2518737304 @default.
• W3164914380 cites W2726970446 @default.
• W3164914380 cites W2766002903 @default.
• W3164914380 cites W2769100897 @default.
• W3164914380 cites W2884281315 @default.
• W3164914380 cites W2954603150 @default.
• W3164914380 cites W3004316830 @default.
• W3164914380 cites W3030199526 @default.
• W3164914380 cites W4385791713 @default.
• W3164914380 cites W68921572 @default.
• W3164914380 doi "https://doi.org/10.3390/pharmaceutics13060804" @default.
• W3164914380 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8227174" @default.
• W3164914380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34071286" @default.
• W3164914380 hasPublicationYear "2021" @default.
• W3164914380 type Work @default.
• W3164914380 sameAs 3164914380 @default.
• W3164914380 citedByCount "3" @default.
• W3164914380 countsByYear W31649143802023 @default.
• W3164914380 crossrefType "journal-article" @default.
• W3164914380 hasAuthorship W3164914380A5001730543 @default.
• W3164914380 hasAuthorship W3164914380A5004710716 @default.
• W3164914380 hasAuthorship W3164914380A5029995906 @default.
• W3164914380 hasAuthorship W3164914380A5032197327 @default.
• W3164914380 hasAuthorship W3164914380A5032443332 @default.
• W3164914380 hasAuthorship W3164914380A5039148956 @default.
• W3164914380 hasAuthorship W3164914380A5056772996 @default.
• W3164914380 hasAuthorship W3164914380A5073051707 @default.
• W3164914380 hasAuthorship W3164914380A5074594600 @default.
• W3164914380 hasAuthorship W3164914380A5080949484 @default.
• W3164914380 hasAuthorship W3164914380A5081374452 @default.
• W3164914380 hasAuthorship W3164914380A5091335333 @default.
• W3164914380 hasBestOaLocation W31649143801 @default.
• W3164914380 hasConcept C106487976 @default.
• W3164914380 hasConcept C126322002 @default.
• W3164914380 hasConcept C150903083 @default.
• W3164914380 hasConcept C170493617 @default.
• W3164914380 hasConcept C185592680 @default.
• W3164914380 hasConcept C2778938600 @default.
• W3164914380 hasConcept C2781047461 @default.
• W3164914380 hasConcept C43617362 @default.
• W3164914380 hasConcept C71924100 @default.
• W3164914380 hasConcept C86803240 @default.
• W3164914380 hasConcept C98274493 @default.
• W3164914380 hasConceptScore W3164914380C106487976 @default.
• W3164914380 hasConceptScore W3164914380C126322002 @default.
• W3164914380 hasConceptScore W3164914380C150903083 @default.
• W3164914380 hasConceptScore W3164914380C170493617 @default.
• W3164914380 hasConceptScore W3164914380C185592680 @default.
• W3164914380 hasConceptScore W3164914380C2778938600 @default.
• W3164914380 hasConceptScore W3164914380C2781047461 @default.
• W3164914380 hasConceptScore W3164914380C43617362 @default.

• next